Loading…

Immune checkpoint expression as prognostic biomarker candidates in non‐small cell lung carcinoma patients

Background Cancer immunotherapy has had an important role in oncologic therapeutics for patients with non‐small cell lung cancer (NSCLC) using checkpoint inhibitors. We will explore the possible prognosis biomarker candidates such as: soluble OX40 (sOX40), OX40L (sOX40L), Glucocorticoid‐induced tumo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2024-09, Vol.130 (4), p.919-928
Main Authors: Porto, Débora Maria, Costa, Guilherme Jorge, Torres, Leuridan Cavalcante, Casarini, Dulce Elena
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Cancer immunotherapy has had an important role in oncologic therapeutics for patients with non‐small cell lung cancer (NSCLC) using checkpoint inhibitors. We will explore the possible prognosis biomarker candidates such as: soluble OX40 (sOX40), OX40L (sOX40L), Glucocorticoid‐induced tumor necrosis factor receptor family‐related receptor (GITR), and their ligand (GITRL), 4‐1BB or tumor necrosis factor receptor superfamily 9 (TNFRS9) and inducible T cell co‐stimulator (ICOS) in peripheral blood of NSCLC patients. Methods Fifty‐eight patients were diagnosed with advanced NSCLC between January 2019 and March 2020. Results High sOX40 and low s4‐1BB levels in smokers compared non‐smoker NSCLC patients. Lower sOX40L levels were found in the male than female (p 
ISSN:0022-4790
1096-9098
1096-9098
DOI:10.1002/jso.27763